title: Epithelial membrane protein-2 (EMP2) and experimental proliferative vitreoretinopathy (PVR).
abstract: OBJECTIVE
  Proliferative vitreoretinopathy (PVR) is believed to result in part from de-differentiation of retinal pigment epithelium (RPE) with cellular migration in the vitreous cavity, membrane formation, and contraction in an aberrant wound-healing strategy. In an in vitro collagen-gel contraction assay, epithelial membrane protein 2 (EMP2) controls contraction through activation of focal adhesion kinase (FAK) in a RPE cell line (ARPE-19). The purpose of this study was to investigate how blocking or altering the level of EMP2 expression changed clinical PVR in an in vivo model.
  
  
  METHODS
  Using the ARPE-19 cell line, the levels of EMP2 modulated through stable transfections of an EMP2 overexpressing construct, EMP2 ribozyme, or vector alone. These transfected cell lines were used in a rabbit model of PVR. The severity of PVR was classified by two masked observers. An EMP2 blocking antibody was also used to decrease functional EMP2 in the PVR model. Immunohistochemistry was used to evaluate EMP2 expression in vivo.
  
  
  RESULTS
  The transfectants with lower levels of EMP2 had significantly less PVR severity than the degree of PVR induced by wild-type cells (p = 0.05). Also, the transfectants with a low-level of EMP2 expression showed a strong trend of less PVR severity than the high-levels EMP2 transfectants (p = 0.06). Blocking EMP2 with a specific polyclonal antibody significantly decreased the level of PVR severity (p = 0.02). PVR membranes were found to be positive for EMP2 expression.
  
  
  CONCLUSIONS
  These in vivo studies support a direct correlation between EMP2 expression and severity of PVR. These results validate the potential for controlling RPE biology through a change in EMP2 expression, and provide a potential therapeutic target for this disease.
authors: Department of Ophthalmology, University of California-Davis, Sacramento, California, USA. dgtelander@ucdavis.edu
authors: David G
authors: DG
authors: Telander
authors: Shawn A
authors: SA
authors: Morales
authors: Sergey
authors: S
authors: Mareninov
authors: Krisztina
authors: K
authors: Forward
authors: Lynn K
authors: LK
authors: Gordon
references: Am J Ophthalmol. 1983 May;95(5):663-7
references: 6846457
references: J Biol Chem. 2007 Sep 7;282(36):26542-51
references: 17609206
references: J Biol Chem. 2002 Oct 25;277(43):41094-100
references: 12189152
references: Nat Protoc. 2007;2(1):67-77
references: 17401340
references: Invest Ophthalmol Vis Sci. 2006 Jan;47(1):364-70
references: 16384986
references: Prog Retin Eye Res. 2002 Jan;21(1):127-44
references: 11906814
references: Mol Neurobiol. 2003 Oct;28(2):159-75
references: 14576454
references: Reprod Biol Endocrinol. 2008 Apr 09;6:15
references: 18400107
references: Prog Retin Eye Res. 2008 Mar;27(2):177-96
references: 18243038
references: Surv Ophthalmol. 1998 Jul-Aug;43(1):3-18
references: 9716190
references: J Dairy Sci. 2004 Jun;87(6):1641-74
references: 15453478
references: Annu Rev Cell Dev Biol. 2003;19:397-422
references: 14570575
references: J Am Soc Nephrol. 2004 Jan;15(1):1-12
references: 14694152
references: Invest Ophthalmol Vis Sci. 1995 May;36(6):990-6
references: 7730033
references: Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1305-11
references: 17325177
references: Invest Ophthalmol Vis Sci. 2009 Jan;50(1):462-9
references: 18469192
references: Blood. 2001 Jun 15;97(12):3890-5
references: 11389031
references: Clin Immunol. 2003 May;107(2):129-36
references: 12763482
references: Invest Ophthalmol Vis Sci. 1995 Nov;36(12):2388-95
references: 7591628
references: Invest Ophthalmol Vis Sci. 1991 May;32(6):1739-48
references: 2032796
references: Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4291-9
references: 17724219
references: Ophthalmologica. 2007;221(2):78-94
references: 17380062
references: Mol Biol Cell. 2004 May;15(5):2073-83
references: 14978215
references: Ophthalmology. 2007 Aug;114(8):1439-47
references: 17331579
references: Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4429-35
references: 19369237
references: Lab Invest. 2004 Oct;84(10):1245-58
references: 15273699
references: Exp Mol Pathol. 2003 Apr;74(2):106-12
references: 12710941
references: Prog Retin Eye Res. 2006 Mar;25(2):149-64
references: 16377232
references: Compr Ophthalmol Update. 2006 Jul-Aug;7(4):179-85
references: 17007731
references: Am J Ophthalmol. 1982 May;93(5):565-72
references: 7081355
references: Exp Eye Res. 2007 Dec;85(6):790-8
references: 17915217
references: Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3112-7
references: 27294805
references: Ophthalmol Clin North Am. 2002 Mar;15(1):81-6
references: 12064085
references: Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4563-9
references: 15557468